XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.2
Other Operating Income And Expenses
 6 Months Ended
Jun. 30, 2025
Analysis of income and expense [abstract]  
Other Operating Income and Expenses
B.15. Other operating income and expenses
Other operating income amounted to €533 million in the first half of 2025 (versus €563 million in the first half of 2024), and Other operating expenses to €2,476 million (versus € 1,977 million in the first half of 2024).
Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
The main items included in Other operating income were: in the first half of 2025, (i) income from pharmaceutical partners of €87 million (versus €121 million in the first half of 2024), of which €70 million came from Regeneron (versus €96 million in the first half of 2024, see table below) and (ii) gains on disposals of assets and operations of €344 million, primarily on divestments of non strategic products (versus €319 million in the first half of 2024).
Other operating expenses for the first half of 2025 included €2,331 million of expenses related to Regeneron (compared with €1,841 million in the first half of 2024), as shown in the table below.
(€ million)June 30, 2025 (6 months)June 30, 2024 (6 months)
Income & expense related to profit/loss sharing under the Monoclonal Antibody Alliance(2,475)(1,934)
Additional share of profit paid by Regeneron towards development costs494 389 
Reimbursement to Regeneron of selling expenses incurred(346)(292)
Total: Monoclonal Antibody Alliance(2,327)(1,837)
Other (mainly Zaltrap and Libtayo)
66 92 
Other operating income/(expenses), net related to Regeneron (2,261)(1,745)
of which amount presented in “Other operating income” 70 96